Lexicon Pharmaceuticals | LXRX - Equity Capital And Reserves


Lexicon Pharmaceuticals reported $202.86M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Akebia Therapeutics USD 25.02M 2.36M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Coherus Biosciences USD 60.84M 17.78M Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Illumina USD 2.84B 162M Jun/2026
Insmed USD 757.49M 52.64M Jun/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
J&J USD 84.97B 3.78B Jun/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
MannKind USD -67.2M 8M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Moderna USD 6.76B 647M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025